EP3528848A4 - Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre des médicaments provoquant des canalopathies - Google Patents
Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre des médicaments provoquant des canalopathies Download PDFInfo
- Publication number
- EP3528848A4 EP3528848A4 EP17861307.1A EP17861307A EP3528848A4 EP 3528848 A4 EP3528848 A4 EP 3528848A4 EP 17861307 A EP17861307 A EP 17861307A EP 3528848 A4 EP3528848 A4 EP 3528848A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- dmpg
- dmpc
- egpg
- lysopg
- protective effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/297,901 US10449193B2 (en) | 2011-06-03 | 2016-10-19 | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
PCT/US2017/057446 WO2018075801A1 (fr) | 2016-10-19 | 2017-10-19 | Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre des médicaments provoquant des canalopathies |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3528848A1 EP3528848A1 (fr) | 2019-08-28 |
EP3528848A4 true EP3528848A4 (fr) | 2020-07-15 |
Family
ID=62019674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17861307.1A Withdrawn EP3528848A4 (fr) | 2016-10-19 | 2017-10-19 | Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre des médicaments provoquant des canalopathies |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3528848A4 (fr) |
JP (1) | JP2019531309A (fr) |
KR (1) | KR20190042775A (fr) |
CN (2) | CN111481508A (fr) |
AU (2) | AU2017345473A1 (fr) |
CA (1) | CA3039596C (fr) |
MX (1) | MX2019004222A (fr) |
WO (1) | WO2018075801A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
EP3697386B1 (fr) * | 2017-10-19 | 2023-07-26 | Signpath Pharma, Inc. | Compositions liquides pour l'usage péroral comprennant dérivés de phosphatidylglycerol et excipients thixotropiques pour le traitement de canalopaties cardiaques causeés par agents pharmacologiques |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120308643A1 (en) * | 2011-06-03 | 2012-12-06 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
US20150343063A1 (en) * | 2014-06-03 | 2015-12-03 | Signpath Pharma Inc. | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
GB9224855D0 (en) * | 1992-11-27 | 1993-01-13 | Smithkline Beecham Plc | Pharmaceutical compositions |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
US20050233970A1 (en) * | 2004-03-23 | 2005-10-20 | Praecis Pharmaceuticals, Inc. | Methods for treating long QT syndrome |
JPWO2008093848A1 (ja) * | 2007-02-02 | 2010-05-20 | サンスター株式会社 | ホスファチジルコリンを含有する炎症マーカー低減組成物 |
JP5638204B2 (ja) * | 2009-05-29 | 2014-12-10 | 国立大学法人 岡山大学 | 経口投与用リポソーム製剤およびその製造方法 |
WO2012094033A1 (fr) * | 2011-01-05 | 2012-07-12 | Livon Laboratories | Procédés de fabrication de liposomes, compositions à base de liposomes préparées en utilisant les procédés, et procédés d'utilisation associés |
EP2814497A4 (fr) * | 2012-02-16 | 2015-12-09 | Vascular Biogenics Ltd | Procédés de traitement du psoriasis et de l'inflammation vasculaire |
AT515178A5 (de) * | 2012-08-31 | 2015-07-15 | Univ North Texas | Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie |
-
2017
- 2017-10-19 CA CA3039596A patent/CA3039596C/fr active Active
- 2017-10-19 CN CN202010289224.4A patent/CN111481508A/zh active Pending
- 2017-10-19 EP EP17861307.1A patent/EP3528848A4/fr not_active Withdrawn
- 2017-10-19 WO PCT/US2017/057446 patent/WO2018075801A1/fr unknown
- 2017-10-19 AU AU2017345473A patent/AU2017345473A1/en not_active Abandoned
- 2017-10-19 JP JP2019518559A patent/JP2019531309A/ja active Pending
- 2017-10-19 KR KR1020197011064A patent/KR20190042775A/ko not_active IP Right Cessation
- 2017-10-19 MX MX2019004222A patent/MX2019004222A/es unknown
- 2017-10-19 CN CN201780064810.5A patent/CN109843331A/zh active Pending
-
2020
- 2020-11-13 AU AU2020267307A patent/AU2020267307A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120308643A1 (en) * | 2011-06-03 | 2012-12-06 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
US20150343063A1 (en) * | 2014-06-03 | 2015-12-03 | Signpath Pharma Inc. | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies |
Non-Patent Citations (1)
Title |
---|
See also references of WO2018075801A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2017345473A1 (en) | 2019-04-18 |
MX2019004222A (es) | 2019-06-10 |
AU2020267307A1 (en) | 2020-12-10 |
CN109843331A (zh) | 2019-06-04 |
WO2018075801A1 (fr) | 2018-04-26 |
JP2019531309A (ja) | 2019-10-31 |
CA3039596C (fr) | 2022-04-12 |
KR20190042775A (ko) | 2019-04-24 |
CA3039596A1 (fr) | 2018-04-26 |
EP3528848A1 (fr) | 2019-08-28 |
CN111481508A (zh) | 2020-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3151837A4 (fr) | Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre des médicaments provoquant des canalopathies | |
EP3538106A4 (fr) | Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des médicaments provoquant des canalopathies | |
EP3442706A4 (fr) | Dispositifs, systèmes et procédés de collecte et de conservation d'échantillon | |
EP3210364B8 (fr) | Systèmes et procédés pour une analyse de sécurité d'application | |
EP3463248A4 (fr) | Dispositifs et procédés d'utilisation de dispositifs d'administration de médicament | |
EP3320347A4 (fr) | Systèmes, procédés et dispositifs de numérisation automatique d'échantillons | |
EP3197518A4 (fr) | Préparation médicamenteuse et dispositifs, méthodes et systèmes de traitement | |
EP3551835A4 (fr) | Systèmes et procédés de tête de puits | |
EP3265217A4 (fr) | Systèmes et procédés à tambour rotatif | |
EP3420456B8 (fr) | Systèmes et procédés anti-répétitions | |
EP3125970A4 (fr) | Orifice d'accès médical, systèmes et procédés pour son utilisation | |
EP3405634A4 (fr) | Dispositif de maintien de porte et système de sécurité | |
EP3400050A4 (fr) | Dispositif de libération de médicament et utilisation | |
EP3150634A4 (fr) | Anticorps anti-muc1 ou fragment de liaison à l'antigène de ce dernier et leur utilisation | |
EP3442567A4 (fr) | Anticorps anti-psma et leur utilisation | |
EP3510986A4 (fr) | Dispositif de mobilité et système de mobilité | |
EP3110352A4 (fr) | Dispositif et système de cage vertébrale et procédés d'assemblage et d'utilisation | |
EP3209766A4 (fr) | Système de traitement d'échantillons tissulaires et procédés associés | |
EP3100683A4 (fr) | Dispositif de traitement de signaux photoacoustiques, système de traitement de signaux photoacoustiques et procédé de traitement de signaux photoacoustiques | |
EP3435665A4 (fr) | Dispositif de surveillance et système de surveillance | |
EP3488431A4 (fr) | Système et procédés de contrôle de sécurité | |
EP3509413A4 (fr) | Systèmes et procédés de récolte de cannabis médicinal | |
EP3136948A4 (fr) | Systèmes et méthodes de détection non intrusive de facultés affaiblies par la drogue | |
EP3483873A4 (fr) | Dispositif et système de réduction du bruit | |
EP3419267A4 (fr) | Dispositif et système de notifications d'urgence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190402 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200615 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101ALI20200608BHEP Ipc: A61K 47/24 20060101AFI20200608BHEP Ipc: A61K 9/127 20060101ALI20200608BHEP Ipc: A61K 31/506 20060101ALI20200608BHEP Ipc: A61P 9/00 20060101ALI20200608BHEP Ipc: A61K 31/683 20060101ALI20200608BHEP Ipc: A61K 31/685 20060101ALI20200608BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220609 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20221020 |